Journal of Pediatric and Adolescent Gynecology
Volume 23, Issue 5 , Pages e133-e136 , October 2010

Tamoxifen as First-line Treatment in a Premenarchal Girl with Juvenile Breast Hypertrophy

  • Korcan Demir

      Affiliations

    • Department of Pediatric Endocrinology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey
    • ,
  • Tolga Unuvar

      Affiliations

    • Department of Pediatric Endocrinology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey
    • ,
  • Sanem Eren

      Affiliations

    • Department of Pediatrics, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey
    • ,
  • Ayhan Abaci

      Affiliations

    • Department of Pediatric Endocrinology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey
    • ,
  • Ece Bober

      Affiliations

    • Department of Pediatric Endocrinology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey
    • Corresponding Author InformationAddress for correspondence: Prof. Dr. Ece Bober, Department of Pediatric Endocrinology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey

References 

  1. Dancey A, Khan M, Dawson J, et al. Gigantomastia—a classification and review of the literature. J Plast Reconstr Aesthet Surg. 2008;61:493
  2. Singh MN, Martin-Hirsch PL, Martin FL. The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century. Med Sci Monit. 2008;14:RA144–RA148
  3. Koves IH, Zacharin M. Virginal breast hypertrophy of an 11-year-old girl. J Paediatr Child Health. 2007;43:315
  4. Baker SB, Burkey BA, Thornton B, et al. Juvenile gigantomastia: Presentation of four cases and review of the literature. Ann Plast Surg. 2001;46:517
  5. Fiumara L, Gault DT, Nel MR, et al. Massive bilateral breast reduction in an 11-year-old girl: 24% ablation of body weight. Plast Reconstr Aesthet Surg. 2008;62:e263–e266
  6. Chang DS, McGrath MH. Management of benign tumors of the adolescent breast. Plast Reconstr Surg. 2007;120:13
  7. Arscott GD, Craig HR, Gabay L. Failure of bromocriptine therapy to control juvenile mammary hypertrophy. Br J Plast Surg. 2001;54:720
  8. Morimoto T, Komaki K, Mori T, et al. Juvenile gigantomastia: report of a case. Surg Today. 1993;23:260–264
  9. O'Hare PM, Frieden IJ. Virginal breast hypertrophy. Pediatr Dermatol. 2000;17:277
  10. Ponzone R, Biglia N, Jacomuzzi ME, et al. Antihormones in prevention and treatment of breast cancer. Ann N Y Acad Sci. 2006;1089:143–158
  11. Abaci A, Buyukgebiz A. Gynecomastia: review. Pediatr Endocrinol Rev. 2007;5:489–499
  12. Kucukaydin M, Kurtoglu S, Okur H, et al. Virginal hypertrophy. Case report. Turk J Pediatr. 1994;36:243–248
  13. Eugster EA, Shankar R, Feezle LK, et al. Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome. J Pediatr Endocrinol Metab. 1999;12:681–686
  14. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–1662
  15. Punyadeera C, Kampsa R, Defrère S, et al. Effects of selective oestrogen receptor modulators on proliferation in tissue cultures of pre- and postmenopausal human endometrium. J Steroid Biochem Mol Biol. 2008;112:102–109
  16. Buzdar AU, Robertson JF. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann Pharmacother. 2006;40:1572–1583

PII: S1083-3188(09)00354-4

doi: 10.1016/j.jpag.2009.11.003

Journal of Pediatric and Adolescent Gynecology
Volume 23, Issue 5 , Pages e133-e136 , October 2010

Article Tools

* Image Usage & Resolution